Shows
Oncology Brothers: Practice-Changing Cancer DiscussionsHow to Treat Early Stage Non-Small Cell Lung Cancer in 2025In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain are joined by Dr. Deepa Rangachari, a thoracic medical oncologist and fellowship program director at Beth Israel Deaconess Medical Center. Together, they dived deep into the treatment algorithms for early-stage non-small cell lung cancer (NSCLC) with a focus on curative intent.
Key topics discussed include:
• The importance of staging and lymph node evaluation in treatment planning.
• The role of neoadjuvant chemoimmunotherapy and the impact of recent trial data, including the CHECKMATE 816 trial.
• The significance of actionable mutations and the use of targeted therapies li...
2025-07-1020 min
Oncology Brothers: Practice-Changing Cancer DiscussionsHow to Treat Early Stage Non-Small Cell Lung Cancer in 2025In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain are joined by Dr. Deepa Rangachari, a thoracic medical oncologist and fellowship program director at Beth Israel Deaconess Medical Center. Together, they dived deep into the treatment algorithms for early-stage non-small cell lung cancer (NSCLC) with a focus on curative intent.Key topics discussed include:• The importance of staging and lymph node evaluation in treatment planning.• The role of neoadjuvant chemoimmunotherapy and the impact of recent trial data, including the CHECKMATE 816 trial.• The significance of actionable mutatio...
2025-07-1020 min
ASCO EducationCancer Topics – Oncology Training – Past, Present, Future Part 2Getting into oncology requires a lot of education and training. How does one deal with the success and stress of such a journey? In Part Two of this ASCO Education Podcast, moderator Dr. Aakash Desai – fellow at the Mayo Clinic along with guests Dr. Madison Conces – fellow at Cleveland Clinic, and Hematology/Oncology fellowship program directors Dr. Lori J. Rosenstein (Gundersen Health System) and Dr. Deepa Rangachari (Beth Israel Deaconess Medical Center) explore the past, present, and future of Oncology Training. They discuss the transition from training to clinical practice (1:02), how to stay current with new treatments and guidelines (6:39) and...
2022-12-2122 minASCO EducationCancer Topics – Oncology Training – Past, Present, Future Part 1Getting into oncology requires a lot of education and training. How does one deal with the success and stress of such a journey? In Part One of this ASCO Education Podcast, moderator Dr. Aakash Desai – fellow at the Mayo Clinic along with guests Dr Madison Conces – Hem/Onc Fellow at Cleveland Clinic, Dr. Lori J. Rosenstein, Hematology and Oncology fellowship program director at Gundersen Health System and Dr. Deepa Rangachari, fellowship program director explore the past, present and future of Oncology Training. They discuss their motivation of pursuing oncology (1:55), the rewards (5:51) and the stresses (8:44) of fellowship, coping with the loss...
2022-12-1426 min
Journal of Clinical Oncology (JCO) PodcastHow Low Can You Go? Impact of Baseline Corticosteroid Use on Immunotherapy Outcomes in Patients With Advanced Non-Small-Cell Lung CancerThis JCO Podcast provides observations and commentary on the JCO article, "Impact of Baseline Steroids on Efficacy of PD-(L)1 Blockade in Patients With NSCLC" by Arbour et al. My name is Deepa Rangachari, and I am an Assistant Professor of Medicine at the Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, Massachusetts, USA. My oncologic specialty is thoracic cancers. For decades, the management of advanced non-small-cell lung cancer has relied on use of cytotoxic chemotherapies with a median overall survival not exceeding one year. As this longstanding therapeutic approach has been...
2018-08-2008 minJournal of Clinical Oncology (JCO) PodcastGetting to the Heart of the Matter: Biomarkers for the Assessment of Trastuzumab-Induced Cardiac DysfunctionBy Deepa Rangachari This podcast focuses on the use of trastuzumab in adjuvant therapy for early stage, Her2-positive breast cancer and ongoing efforts to identify predictive and prognostic biomarkers for the assessment of treatment-related cardiac toxicity. Related Article: Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy
2016-10-2611 min